
# Diagnosing and Treating Cases of Suspected Canine Hyperadrenocorticism or Addison's Disease

**IMPORTANT:** Review history of any administration of corticosteroids as these may influence the reported results.

## Diagnose

#### **ACTH Stimulation Test**

Diagnostic Protocol for Cases of Suspected Canine Hyperadrenocorticism or Addison's Disease



\*Remaining Cortrosyn<sup>®</sup> can be aliquoted into 1-mL syringes containing 0.2 mL Cortrosyn each. Store aliquoted syringes for up to six months, or vial can be refrigerated for up to one month.<sup>1</sup>


\*\*Take care not to exceed 0.1 mg/kg of dexamethasone.

1. Feldman EC, Nelson RW. *Canine and Feline Endocrinology and Reproduction*, 3rd ed. Philadelphia, PA: WB Saunders; 2003:305.

# **Treat**

#### Mitotane (Lysodren®) Dosing and Monitoring

Treatment of Pituitary Dependent Canine Hyperadrenocorticism




patient, perform electrolytes and ACTH stimulation test and treat accordingly.

\*If ACTH stimulation is still  $>5 \mu g/dL$  after initial 5–10 days of additional loading, continue loading dose for an additional 5–10 days, observing for adverse reactions.

### **Treat**

#### Low-Dose Dexamethasone Suppression Protocol

For Cases of Suspected Canine Hyperadrenocorticism



\*Wait a minimum of 48 hours before repeating if a


technical error in the protocol occurred.

\*\*Take care not to exceed 0.1 mg/kg of dexamethasone.

## Treat


**High-Dose Dexamethasone Suppression Protocol** 

For Determination of Pituitary-Dependent vs. Adrenal Tumor Canine Hyperadrenocorticism



\*Take care not to exceed 0.1 mg/kg of dexamethasone.

# Trilostane (Vetoryl®) Dosing and Monitoring\*



\*Modified from "Treatment and Monitoring of Hyperadrenocorticism" flowchart published by Dechra Ltd., 2009.

© 2017 IDEXX Laboratories. Inc. All rights reserved. • 06-0008966-00

The recommendations contained in this document are intended to provide general guidance only. As with any diagnosis or treatment, you should use clinical discretion with each patient based on a complete evaluation of the patient, including history, physical examination and complete laboratory data profile. With respect to any drug therapy or monitoring program, you should refer to product inserts for a complete description of dosages, indications, interactions and cautions.

Lysodren is a registered trademark of Bristol-Meyers Squibb Company or one of its divisions or subsidiaries. Cortrosyn is a registered trademark of Amphastar Pharmaceuticals, Inc. Vetoryl is a trademark of Dechra Ltd All other ®/TM marks are owned by IDEXX Laboratories, Inc. or its affiliates in the United States and/or other countries The IDEXX Privacy Policy is available at idexx.com

